View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 5, 2022

PhaseBio reports positive data from Phase IIb antibody trial in uncontrolled bleeding

Findings showed that bentracimab treatment substantially restored platelet function within five minutes of dosing.

PhaseBio Pharmaceuticals has reported positive data from the Phase IIb clinical trial of bentracimab which has been designed to treat patients with uncontrolled bleeding or requiring surgery. 

A new, recombinant, human monoclonal antibody antigen-binding fragment, bentracimab is created to reverse ticagrelor’s antiplatelet activity.

The multicentre, double-blind, randomised, placebo-controlled trial enrolled 205 older subjects aged 50-80 years.

All these participants received dual anti-platelet therapy comprising ticagrelor and low-dose aspirin. Subsequently, 154 subjects were given bentracimab while 51 received placebo. 

Reversing ticagrelor’s platelet function inhibition in bentracimab-treated participants versus placebo was the primary endpoint of the trial.

Findings showed that bentracimab treatment substantially restored platelet function within five minutes of dosing.

Furthermore, it did not cause any drug-related serious adverse events or thrombotic events in the trial. 

Bentracimab was demonstrated to be well tolerated, with only non-serious adverse events reported in the trial. 

The safety and efficacy data from this trial are in line with those from the concluded Phase I and Phase IIa trials.

PhaseBio chief medical officer John Lee said: “The trial results provide support for the safety and efficacy profile of bentracimab and also provide key safety data that will be included as part of our planned Biologics License Application (BLA) submission to the FDA, which remains on track for mid-2022.”

The Phase IIb trial was carried out in parallel with the Phase III REVERSE-IT trial of bentracimab underway, as agreed following an End-of-Phase 1 meeting with the US Food and Drug Administration (FDA).

In December last year, the company voluntarily halted the Phase IIb trial of pemziviptadil (PB1046) for the treatment of pulmonary arterial hypertension in adults.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy